SG11202007513PA - Modified pluripotent stem cells and methods of making and use - Google Patents

Modified pluripotent stem cells and methods of making and use

Info

Publication number
SG11202007513PA
SG11202007513PA SG11202007513PA SG11202007513PA SG11202007513PA SG 11202007513P A SG11202007513P A SG 11202007513PA SG 11202007513P A SG11202007513P A SG 11202007513PA SG 11202007513P A SG11202007513P A SG 11202007513PA SG 11202007513P A SG11202007513P A SG 11202007513PA
Authority
SG
Singapore
Prior art keywords
making
methods
stem cells
pluripotent stem
modified pluripotent
Prior art date
Application number
SG11202007513PA
Inventor
Eric H Gschweng
Rajul JAIN
Yong Ouyang
Garcia Arianne Perez
Margo Roberts
Rodriguez Ruben Alvarez
Drake Smith
Xingliang Zhou
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of SG11202007513PA publication Critical patent/SG11202007513PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202007513PA 2018-02-16 2019-02-15 Modified pluripotent stem cells and methods of making and use SG11202007513PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862710591P 2018-02-16 2018-02-16
US201862673624P 2018-05-18 2018-05-18
PCT/US2019/018310 WO2019161271A1 (en) 2018-02-16 2019-02-15 Modified pluripotent stem cells and methods of making and use

Publications (1)

Publication Number Publication Date
SG11202007513PA true SG11202007513PA (en) 2020-09-29

Family

ID=65529926

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007513PA SG11202007513PA (en) 2018-02-16 2019-02-15 Modified pluripotent stem cells and methods of making and use

Country Status (10)

Country Link
US (1) US20210040449A1 (en)
EP (1) EP3752599A1 (en)
JP (2) JP2021513839A (en)
KR (1) KR102618231B1 (en)
CN (1) CN112534044A (en)
AU (2) AU2019222550B2 (en)
CA (2) CA3177757A1 (en)
IL (1) IL276523A (en)
SG (1) SG11202007513PA (en)
WO (1) WO2019161271A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
AU2016349504B2 (en) * 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CN109439626B (en) * 2018-11-09 2022-10-14 复旦大学附属中山医院 Composition for obtaining Th22 cells in vitro and application thereof
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs
CN114945376A (en) * 2019-11-05 2022-08-26 希望之城公司 Generation of chimeric antigen receptor modified T cells from stem cells and therapeutic uses thereof
KR20210095586A (en) * 2020-01-23 2021-08-02 주식회사 강스템바이오텍 Off-the-shelf stem cell and immune cell, and a pharmaceutical composition
MX2023004326A (en) * 2020-11-04 2023-07-04 Fate Therapeutics Inc Multiplexed engineered ipsc and immune effector cells targeting solid tumors.
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
WO2023001833A1 (en) * 2021-07-19 2023-01-26 Repairon Immuno Gmbh Method of producing a population of immune cells from pluripotent stem cells
CA3234902A1 (en) * 2021-10-20 2023-04-27 Emily CARRON Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors
KR20230131816A (en) 2022-03-04 2023-09-14 주식회사 툴젠 Hypoimmunogenic stem cells, hypoimmunogenic cells differentiated or derived from stem cells, and method for producing the same
WO2024003349A1 (en) 2022-07-01 2024-01-04 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
KR102062407B1 (en) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
BR112013024395B1 (en) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center ADOPTIVE COMPOSITIONS OF CELL IMMUNOTHERAPY AND METHOD FOR MANUFACTURING SUCH COMPOSITION
US20140134195A1 (en) * 2011-04-20 2014-05-15 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PT3300745T (en) 2013-02-15 2019-11-27 Univ California Chimeric antigen receptor and methods of use thereof
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
MX2015015638A (en) * 2013-05-13 2016-10-28 Cellectis Methods for engineering highly active t cell for immunotherapy.
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
KR102238226B1 (en) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Human application of engineered chimeric antigen receptor (car) t-cells
WO2015080981A1 (en) 2013-11-27 2015-06-04 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
KR102228828B1 (en) * 2014-03-11 2021-03-16 셀렉티스 Method for generating t-cells compatible for allogenic transplantation
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
BR112017005245A2 (en) 2014-09-19 2017-12-12 Regeneron Pharma genetically modified nonhuman animal, methods for producing t cell, t cell hybridoma, nucleic acid, specific antibody, human cell, genetically modified nonhuman animal and for inducing an immune response, cell, t cell hybridoma, acid nucleic acid, specific antibody, chimeric antigen receptor, non-human embryo, chimeric antigen receptor locus, and nucleic acid composition.
CA2969704C (en) 2014-12-05 2023-05-02 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells
WO2016183041A2 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
JP6983771B2 (en) 2015-10-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California A method for producing T cells from stem cells and an immunotherapeutic method using the T cells.
CN108699132B (en) * 2015-12-18 2023-08-11 桑格摩生物治疗股份有限公司 Targeted disruption of MHC cell receptors
KR20240000616A (en) * 2016-04-15 2024-01-02 메모리얼 슬로안 케터링 캔서 센터 Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
SG11201810697QA (en) * 2016-06-07 2018-12-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma

Also Published As

Publication number Publication date
AU2019222550A1 (en) 2020-08-27
CA3177757A1 (en) 2019-08-22
KR102618231B1 (en) 2023-12-28
AU2023200405A1 (en) 2023-02-23
WO2019161271A1 (en) 2019-08-22
AU2019222550B2 (en) 2022-10-27
JP2023109921A (en) 2023-08-08
CA3090793A1 (en) 2019-08-22
IL276523A (en) 2020-09-30
US20210040449A1 (en) 2021-02-11
EP3752599A1 (en) 2020-12-23
KR20200120939A (en) 2020-10-22
JP2021513839A (en) 2021-06-03
CN112534044A (en) 2021-03-19

Similar Documents

Publication Publication Date Title
IL276523A (en) Modified pluripotent stem cells and methods of making and use
EP3423564A4 (en) Microglia derived from pluripotent stem cells and methods of making and using the same
IL275433A (en) Artificial antigen presenting cells and methods of use
EP3334820A4 (en) Induced extended pluripotent stem cells, methods of making and using
SG10201913687VA (en) Generation of midbrain-specific organoids from human pluripotent stem cells
PL3145517T3 (en) Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
IL241930B (en) Isolated naive pluripotent stem cells and methods of generating same
IL263265A (en) Use of mesenchymal stem cells and parts thereof
EP3198004A4 (en) TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE
EP3568467A4 (en) Modified t cells and methods of their use
IL285619A (en) Universal donor stem cells and related methods
PT3551748T (en) Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof
EP3589293A4 (en) Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors
GB201907690D0 (en) Electrochemical cells and methods of making and using thereof
IL261623A (en) Stem cells expressing mesenchymal and neuronal markers, compositions thereof, and methods of preparation thereof
PT3606467T (en) Prosthetic valves and methods of making
IL280240A (en) Nef-containing t cells and methods of producing thereof
IL275037A (en) Crispr-cas9 modified cd34plus human hematopoietic stem and progenitor cells and uses thereof
IL290297A (en) Modified cytotoxic t cells and methods of use thereof
IL288091A (en) Methods of characterizing and utilizing agent-condensate interactions
IL263341A (en) Stem cell material, compositions, and methods of use
IL274436B1 (en) Islet cell manufacturing compositions and methods of use
HK1258782A1 (en) Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
EP3574088A4 (en) Methods of enhancing engraftment activity of hematopoietic stem cells
EP4041255A4 (en) Modified stem cells and methods of use thereof